The xF+ Liquid Biopsy Panel is an innovative test that detects cancer-related genetic mutations using circulating tumor DNA (ctDNA) from blood samples. This non-invasive assay covers a broad range of 523 genes, allowing for the detection of key genetic signatures associated with various solid tumors. Its design focuses on identifying single nucleotide variants, insertions, deletions, and copy number variations, along with specific gene fusions and MSI-H status.<br/><br/>This test empowers clinicians with real-time insights into tumor dynamics, enabling the tracking of genetic changes over time without the need for repeated tissue biopsies. Such monitoring is crucial for assessing the effectiveness of treatments and for making timely therapeutic decisions, especially in patients with advanced cancer.<br/><br/>The xF+ panel's ability to capture tumor heterogeneity offers a comprehensive snapshot of the genomic landscape of a patient’s cancer, supporting the personalization of treatment strategies. Its high sensitivity and specificity in detecting low-frequency variants make it a powerful tool in ongoing cancer management, ensuring therapies are precisely tailored to each patient's genetic profile.
